These Houston-area entrepreneurs have something to celebrate this week. Photos courtesy of EY

Four entrepreneurs whose companies are in or near the Houston metro area have been named winners in Ernst & Young’s Entrepreneur Of The Year regional competition and now will head to the national competition.

Local winners of the Entrepreneur Of The Year 2022 Central South Award are:

  • Elliott Bouillion, founder and executive chairman of Bellaire-based Resource Environmental Solutions. The company helps clients with environmental mitigation, stormwater management and water quality, and climate adaptation and flood resilience.
  • Blake Brannon, founder and president of Brenham-based Brannon Industrial Group. The company buys and recycles scrap metal, provides waste and recycling services, rents out portable toilets, and offers sustainable printing services.
  • Dr. Juliet Breeze, founder and CEO of Houston-based Next Level Medical, which operates membership-model urgent care clinics.
  • Jamie Welch, president, CEO, and chief financial officer of Houston-based Kinetic Holdings, a midstream oil and natural gas operator in the Delaware Basin of West Texas and northern New Mexico.

Among the criteria used to select the regional winners were purpose, growth, impact, and entrepreneurial spirit.

“Each of these entrepreneurs has exhibited curiosity, ingenuity, and courage, and we are proud to celebrate this outstanding group of leaders and welcome them as valuable members of our Entrepreneur Of The Year community,” says Anna Tallent, co-director of the awards’ Central South program.

As regional award winners, these entrepreneurs will be considered for the Entrepreneur Of The Year 2022 national awards, which will be presented in November. The overall Entrepreneur Of The Year winner at the national level then will move on to the EY World Entrepreneur Of The Year program, which will name its top winner in June 2023.

In a news release, Breeze says she’s honored to be given such a prestigious award.

“This award is further validation that at Next Level, we are really on to something. Healthcare needs to be available to patients when and where they need it,” Breeze says.

Aside from the Houston-area winners, here are the other recipients of this year’s Entrepreneur Of The Year Central South Award:

  • CEO Amanda Baldwin and founder and Chairwoman Holly Thaggard of San Antonio-based Supergoop! The company makes and sells sunscreen-based skincare products.
  • Cory Brymer, founder and CEO of Hutto-based BryComm, a provider of technology and security infrastructure services.
  • William Chan, co-founder and CEO of Austin-based Iodine Software, a provider of AI-powered software for the healthcare industry.
  • Todd Dipaola, founder and CEO of Austin-based InMarket, which operates a platform for localized advertising.
  • Dr. David Ferguson, co-founder, president, and CEO of San Antonio-based Celebrate Dental & Braces, which has offices in five states.
  • Mark Floreani, co-founder and CEO of Austin-based FloSports, a streaming service for sporting events.
  • James Garvey, founder and CEO of Austin-based Self Financial, which offers credit-building loans.
  • Tim Heyl, founder and CEO of Austin-based Homeward, whose loans help buyers make all-cash offers for homes.
  • Joel Kocher, co-founder and CEO of Austin- based HumanN, a provider of superfood products.
  • JeVon McCormick, president and CEO of Austin-based book publisher Scribe Media.
  • Thomas Thill, CEO of San Antonio-based AmeriVet Veterinary Partners, an owner and operator of veterinary practices.
Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

Houston researchers report promising first in-human trial for implantable cancer therapy

cancer breakthrough

When it comes to cancer remedies, the treatment can be as challenging for the body as its cause. But what if immunotherapy could be localized? That’s precisely what a Houston team may soon make a reality.

Rice University researchers, in partnership with MD Anderson Cancer Center, recently published their findings from the first in-human trial of an implantable cancer-fighting treatment in the journal Clinical Cancer Research. The paper details testing of AVB-001, encapsulated cells engineered to release interleukin-2 (IL-2)—a naturally occurring signaling protein that boosts immunity—in the peritoneal cavities of 14 patients. The goal is to avoid the toxicity usually experienced with less targeted treatments, as well as find a solution to IL-2s’ abbreviated half-lives.

“Traditional IL-2 therapy has shown potent antitumor activity, but its clinical use has been limited by severe side effects and delivery challenges,” Omid Veiseh, director of the Rice Biotech Launch Pad, professor of bioengineering at Rice and a senior author on the study, said in a press release. “This platform allows us to localize and sustain cytokine exposure directly where tumors reside while minimizing systemic toxicity.”

Serous ovarian carcinoma is especially well-suited to the use of AVB-001 because it tends to spread throughout the abdomen. After a minimally invasive laparoscopic procedure, patients implanted with the cells were noted to tolerate the treatment well. Half of the enrolled patients’ cancer was stabilized, with several among them reporting extended signs of benefit. No maximum tolerated dose was reached and there were no life-threatening events tied to the study.

If that sounds like less-than-earth-shaking results, this is only the beginning. The capsules were implanted for about one week because IL-2 activity drops off after that. The researchers now know that further testing should include either higher levels, repeated doses, or a combination thereof, in order to create stronger advances.

The team has already made early headway on this next step. Preclinical studies in nonhuman primates were not only tolerated well, but without added toxicity, the apes had consistent pharmacological effects.

“This is a foundational step,” Veiseh explained. “We now have evidence that the platform is safe, biologically active and potentially scalable. The next phase is optimizing dosing and exploring combination therapies to unlock its full clinical potential.”

The combination would also include a checkpoint inhibitor, which might improve AVB-001’s tumor-fighting power. “What is exciting is that we are not just delivering a drug, we are programming a microenvironment,” added Dr. Amir Jazaeri, professor of gynecologic oncology at MD Anderson, member of the Rice Biotech Launch Pad’s clinical advisory board and a senior author on the study. “This opens the door to combination strategies that could amplify immune responses in ways that have not been feasible before.”

Houston startup raises $6M to scale home-based healthcare platform

fresh funding

As healthcare systems race to expand care beyond hospitals and into the home, investors are placing bigger bets on the infrastructure needed to make that shift possible.

This month, Rosarium Health announced it has raised $6 million in seed funding led by Kalos Ventures, with participation from ResilienceVC, Rock Health Capital, Symphonic Capital, Black Tech Nations Ventures and others.

The investment will help the Houston-based startup continue to build its platform, which features a national network of 800-plus clinicians and 3,000-plus contractors to coordinate home accessibility upgrades and modifications for seniors and people living with disabilities.

For founder and CEO Cameron Carter, the company’s mission grew out of firsthand caregiving experiences.

“From my own personal caregiving experiences, I realized that the benefits exist on paper, but not in reality,” Carter said in a news release. “Families are being left to figure out the paperwork and installations all on their own, which shouldn’t be how this works.”

While Medicare Advantage and Medicaid plans have expanded coverage for home-based services and accessibility modifications, the logistics behind delivering those services often remain fragmented.

Rosarium’s platform coordinates the entire process, from clinical assessments and referrals to contractor management, documentation, reimbursement and installation.

“A clinician can document that a home isn’t safe and a plan can approve a benefit, but there’s no one that’s responsible for making sure the work actually gets done,” Carter says. “We built the missing piece.”

The company was founded in 2021 as Rose Health and was a 2023 participant in the Texas Medical Center’s Accelerator for HealthTech program. It has scaled quickly, building a network of more than 800 clinicians and 3,000 contractors across 34 states.

Rosarium is currently in-network for 1.2 million Medicare and Medicaid lives, with projected coverage expected to reach nearly 4 million by the end of the year, according to the release.

“We’re excited to back Cameron because he and the team at Rosarium are building the infrastructure healthcare needs right now to make the home a safe and comfortable place of care,” Kate Ballinger, investor at Kalos Ventures, added in the release.

As part of the recent investment, Ballinger will join Rosarium’s board of directors.

With eyes on the future, Rosarium plans to grow its partnerships with Medicaid and Medicare Advantage plans, including CalViva and Community Health Plan of Imperial Valley, strengthening its presence in California while expanding access to underserved communities.

Additionally, Carter predicts that home-based healthcare will be part of a broader transformation happening across the industry.

“There’s a growing recognition that health outcomes are shaped by what happens in the home,” he said in the release. “The future of healthcare isn’t just treating people after something goes wrong. It’s creating environments that help prevent those problems in the first place.”